600222.SH
太龙药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 7.55
−3.70%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.8B | 1.8B | 1.9B | 2.1B | 2.0B |
| Cost of Revenue | 1.3B | 1.3B | 1.4B | 1.5B | 1.5B |
| Gross Profit | 497.4M | 492.2M | 496.9M | 564.7M | 472.1M |
| Operating Expenses | |||||
| R&D Expense | 71.5M | 67.8M | 100.9M | 127.7M | 116.5M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 128.0M | 127.1M | 136.7M | 141.6M | 134.5M |
| Selling & Marketing Expense | 129.0M | 131.2M | 170.9M | 197.9M | 183.0M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 399.4M | 396.3M | 477.2M | 530.7M | 506.0M |
| Cost and Expenses | 1.7B | 1.7B | 1.9B | 2.0B | 2.0B |
| Operating Income (EBIT) | 77.6M | 77.7M | 35.7M | 44.2M | (70.8M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 77.4M | 77.5M | 35.1M | 43.0M | (82.8M) |
| Income Tax Expense | 11.8M | 11.6M | (18.4M) | (1.9M) | (7.1M) |
| Bottom Line | |||||
| Net Income | 61.1M | 60.0M | 50.5M | 43.6M | (72.2M) |
| Earnings from Cont. Ops | 65.6M | 65.9M | 53.5M | 44.8M | (75.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 61.1M | 60.0M | 50.5M | 43.6M | (72.2M) |
| Per Share | |||||
| Basic EPS | CN¥0.11 | CN¥0.11 | CN¥0.09 | CN¥0.08 | (CN¥0.13) |
| Diluted EPS | CN¥0.11 | CN¥0.11 | CN¥0.09 | CN¥0.08 | (CN¥0.13) |
| Revenue Per Share | CN¥3.22 | CN¥3.18 | CN¥3.49 | CN¥3.68 | CN¥3.49 |
| Shares | |||||
| Basic Shares Outstanding | 553.4M | 553.0M | 556.4M | 562.7M | 562.3M |
| Diluted Shares Outstanding | 553.4M | 553.0M | 556.4M | 562.7M | 562.3M |
| Profitability Metrics | |||||
| EBITDA | — | 138.5M | 95.9M | 103.2M | (18.6M) |
| D&A | — | 60.8M | 60.2M | 59.1M | 52.2M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026